CENTEK(000931) 上海证券报·2025-04-02 18:19Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has been selected in the 10th batch of national drug centralized procurement for its product, Naloxone Hydrochloride Injection, which is expected to positively impact the company's future performance and market presence [1][2]. Group 1: Product Information - Product Name: Naloxone Hydrochloride Injection - Dosage Form: Injection - Specification: 1ml:1mg - Packaging: 10 vials/box - Indications: Used for reversing respiratory depression caused by opioid drugs, treating opioid overdose, and diagnosing acute opioid overdose [1][2]. Group 2: Procurement Details - Selected Price: 0.99 yuan per vial - Supply Provinces: Inner Mongolia, Liaoning, Jilin, Hunan, Qinghai - Backup Supply Provinces: Beijing, Tianjin, Zhejiang, Anhui, Jiangxi - Selected Company: Beijing Huasu Pharmaceutical Co., Ltd. [2]. Group 3: Impact on the Company - The selected product is classified as a Class A product under the national medical insurance scheme, with a procurement period from the selection date until December 31, 2027 - Medical institutions will prioritize the use of selected products, which is expected to enhance the company's sales channels and market share for Naloxone Hydrochloride Injection - The successful implementation of procurement contracts will contribute positively to the company's operational performance and long-term development [2].